Dialysis services revenue grew by 5% to $2,285m and dialysis product revenue increased by 6% to $751m.
North America revenue increased by 1% to $1,977m, which includes the impact of the new Medicare end-stage renal disease prospective payment system in the US.
International revenue increased by 14% to $1,055m.
Operating income (EBIT) for the first quarter of 2011 increased by 5% to $445m compared to $425m in the first quarter of 2010.
Net income attributable to FMC for the first quarter of 2011 was $221m, an increase of 5%, compared to the corresponding quarter of 2010.
Fresenius Medical Care CEO Ben Lipps said they are pleased to report a successful first quarter of 2011 with strong operational performance – despite the expected implementation challenges posed by the new Medicare end-stage renal disease prospective payment system in the US.
"We would again like to express our appreciation to the Centers for Medicare & Medicaid Services (CMS) and the Administration for making this correction, and for their willingness in the past years to work with the entire kidney care community in the process of establishing the new reimbursement system, helping to improve the quality of life of all dialysis patient covered by Medicare," Lipps said.
